Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)

Market Cap	38.36B -14.1%
Revenue (ttm)	7.35B -10.1%
Net Income	1.58B -28.1%
EPS	0.24 -27.3%
Shares Out	6.56B
PE Ratio	24.38
Forward PE	16.71
Dividend	0.05 (0.83%)
Ex-Dividend Date	Feb 10, 2026

Volume	8,105,800
Average Volume	31,521,635
Open	5.77
Previous Close	5.85
Day's Range	5.77 - 5.83
52-Week Range	5.73 - 7.30
Beta	0.42
RSI	29.66
Earnings Date	Mar 27, 2026

About SHE:002252

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The company was founded in 1988 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 3,350
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002252

Financial Performance

In 2025, SHE:002252's revenue was 7.35 billion, a decrease of -10.13% compared to the previous year's 8.18 billion. Earnings were 1.58 billion, a decrease of -28.10%.